Vosoritide, a modified form of C-type natriuretic peptide (CNP) known as the CNP-39 analogue BMN111 (BioMarin Pharmaceutical, San Rafael, Calif, USA), which has been engineered to resist degradation and increase the half-life, was first approved in August 2021 in the EU and became the first medical treatment for achondroplasia in patients aged 2 years and older. This evidence concerns the gene CNP and achondroplasia.